Amgen Plugs Away On Repatha, With Hope For New Monthly Product

In a very strong second-quarter earnings report, Amgen reports just $27m in worldwide sales for cholesterol-busting PCSK9 inhibitor Repatha, as reimbursement continues to present a big hurdle.

Amgen Inc. is plugging away with the cholesterol drug Repatha (evolocumab), which had just $27m in worldwide sales in the second quarter, amid continued reimbursement challenges, and has hopes that launching a monthly version of the drug will give it an edge.

Amgen’s Repatha and Sanofi/Regeneron Pharmaceuticals Inc.’s competing PCSK9 inhibitor Praluent (alirocumab) were approved in the summer of 2015,...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Drug Pricing

More from Scrip